US Patent 5,631,020: Scope, Claim Content, and Landscape (Microcapsule Redispersion for Prolonged Release)
US Patent 5,631,020 protects a specific prolonged-release injectable platform built around a defined polymer matrix (lactic acid-glycolic acid, “PLGA” with defined comonomer ratio and molecular weight), a defined post-processing sequence (redispersion before solidification), a defined reconstitution outcome (greater stability vs no redispersion), and a defined payload peptide (the water-soluble drug enumerated in the claims). The claims also lock the particle size and the excipient set.
What is the core protected invention in 5,631,020?
Claim 1 defines a method, and claim 3 defines the resulting product, both centered on this combination:
- Starting material (spherical microcapsule)
- Average diameter: 2 to 200 μm
- Payload: particles containing a water-soluble drug
- Matrix polymer: PLGA with defined parameters
- Comonomer ratio: about 100/0 to 50/50 (lactic/glycolic)
- Average molecular weight: about 5,000 to 200,000
- Key method step (redispersion)
- The spherical microcapsule is redispersed.
- Defined excipient for redispersion
- Excipients are limited to one selected from:
- mannitol
- sorbitol
- lactose
- glucose
- Solidification
- Redispersed mixture is then solidified.
- Reconstitution performance limitation
- After reconstitution in a vehicle for injection, the resulting microcapsule provides greater stability than if no redispersing step is performed.
- Specific water-soluble drug (payload identity limitation)
- The water-soluble drug is:
- (Pyr) Glu-His-Trp-ser-Tyr-D-Leu-Leu-Arg-Pro-NH-C2 H5
The invention scope is therefore not “any PLGA microcapsule.” It is “a redispersed-and-solidified PLGA microcapsule formulation of a specific peptide, using a narrow polymer characterization window, defined excipient options, and tied to a stability benefit.”
What do the independent and dependent claims cover?
Claim 1 (method)
Claim 1 is the principal scope anchor. It combines method process features, formulation composition constraints, and a payload identity.
Claim 1 limitations (all required):
- Method for producing a prolonged release microcapsule for injection
- Redispersing a spherical microcapsule having:
- average diameter 2 to 200 μm
- Microcapsule contains:
- particles with a water-soluble drug
- Particles are dispersed in a spherical microcapsule matrix of:
- PLGA where:
- comonomer ratio is about 100/0 to 50/50
- average molecular weight is about 5,000 to 200,000
- Redispersion vehicle/excipient is selected from:
- mannitol, sorbitol, lactose, glucose
- After redispersion, solidifying
- Result: upon reconstitution in a vehicle for injection it provides:
- greater stability than if no redispersing step is performed
- Payload is the specific peptide:
- (Pyr) Glu-His-Trp-ser-Tyr-D-Leu-Leu-Arg-Pro-NH-C2 H5
Claim 2 (dependent: specific PLGA composition)
Claim 2 narrows Claim 1 by fixing the polymer comonomer ratio:
All other Claim 1 features remain required.
Claim 3 (product-by-method)
Claim 3 is a product claim defined by the method of Claim 1:
- A prolonged release microcapsule for injection produced by the method of claim 1
This is a classic “product-by-process” structure. It does not explicitly broaden beyond Claim 1’s process-defined constraints; it asserts that the microcapsule made by that method has protected product scope.
How narrow is the claim scope from a competitive design-around view?
1) Payload identity is a hard limiter
Claim 1 expressly requires the water-soluble drug to be (Pyr) Glu-His-Trp-ser-Tyr-D-Leu-Leu-Arg-Pro-NH-C2 H5. Any competitor using a different peptide payload is outside Claim 1 and Claim 3 even if the PLGA and processing are identical.
From an engineering perspective, that payload lock typically dominates freedom-to-operate unless the competitor’s product targets the same active.
2) Polymer specs constrain formulation variables
The matrix must be PLGA with:
- lactic/glycolic ratio: about 100/0 to 50/50
- PLGA average molecular weight: about 5,000 to 200,000
A design-around can target polymer selection outside these ranges. Even within the ranges, dependent Claim 2 further locks comonomer ratio to 75/25.
3) Particle size range reduces generic “microcapsule” coverage
The starting spherical microcapsule must be 2 to 200 μm. If the competitor makes substantially smaller or larger spherical particles, the claim terms are harder to meet.
4) Excipient list is limited
Only one excipient is selected from:
- mannitol, sorbitol, lactose, glucose
Substituting another excipient (or combination outside the claim language) targets a literal avoidance route.
5) Process sequence matters: redispersion step tied to stability
The method requires:
- redispersing
- then solidifying
- and requiring a stability advantage after reconstitution vs no redispersion
The stability limitation is outcome-based. It supports arguments of nonobviousness and distinguishes from prior microencapsulation practices that do not use redispersion before solidification. It can also become the focus of infringement and prosecution history arguments.
What does “greater stability if no redispersing step is performed” likely mean in practice?
While the claim does not specify the stability metric (e.g., potency loss, aggregation, deamidation rate), it creates a comparative performance element that can be tested.
In enforcement terms, this tends to become:
- a factual question (does redispersion improve stability after reconstitution?), and
- a product characterization question (does the accused formulation actually behave as required?).
Because Claim 3 is product-by-method, the comparator condition can also be addressed by process analytics and reconstitution stability experiments.
What is the likely patent landscape around this claim set?
The landscape for microcapsule prolonged release injectables with PLGA, peptide payloads, and lyophilized or reconstitutable dosage forms commonly includes prior art across four clusters:
-
PLGA microencapsulation of peptides
- Prior art typically discloses PLGA microcapsules for sustained release and peptide stabilization.
-
Lyophilized/reconstitutable microcapsules
- Excipient selection (sugars and polyols like mannitol/sorbitol/lactose) is frequently used for freeze-drying and reconstitution stability.
-
Polymer selection and PLGA parameter windows
- Comonomer ratio and molecular weight range are frequently varied to tune drug release and encapsulation.
-
Reconstitution and stability enhancement methods
- Stabilizing peptides against aggregation/degradation after reconstitution is a frequent theme.
What 5,631,020 adds is the specific combination of:
- a redispersion step applied to a spherical microcapsule before solidification,
- limited excipient set,
- specified PLGA specs, and
- a specific peptide identity, with
- a comparative stability advantage tied to the presence/absence of the redispersion step.
Competitive implication
- If a competitor uses the same peptide and broadly similar microcapsule parameters but does not implement the “redispersing step then solidifying” sequence, they can aim to avoid the process limitation.
- If a competitor uses the same redispersion concept but changes polymer parameters outside the claim window, they can target literal avoidance.
- If a competitor uses different stabilizing excipients beyond the claim list, they can target the excipient limitation.
What would infringement analysis prioritize?
For Claim 1, a practical claim chart would check these elements in order:
| Claim element |
What must be shown for infringement |
| Prolonged release microcapsule for injection |
Accused product is designed for sustained/prolonged release and delivered by injection |
| Spherical microcapsule diameter |
Starting microcapsule or relevant material has average diameter 2–200 μm |
| PLGA matrix specs |
Lactic/glycolic ~100/0 to 50/50 and MW ~5,000–200,000 |
| Payload identity |
Water-soluble drug equals (Pyr) Glu-His-Trp-ser-Tyr-D-Leu-Leu-Arg-Pro-NH-C2 H5 |
| Redispersion step |
Manufacturing includes redispersion before solidification |
| Excipient selection |
Excipient used in redispersion is mannitol/sorbitol/lactose/glucose |
| Solidification step |
Redispersion mixture is solidified after redispersion |
| Comparative stability |
Reconstituted formulation shows greater stability vs no redispersing step |
For Claim 3, the analysis shifts to whether the accused product is made by a method meeting all Claim 1 steps.
Where are the high-risk areas for third parties?
| Risk driver |
Why it is high-risk under this claim set |
| Same peptide payload |
Payload identity is explicit, leaving little flexibility if the competitor targets the same drug |
| Similar PLGA parameters |
Many sustained-release PLGA products land in similar polymer windows, raising the chance of partial overlap |
| Use of standard excipients |
Mannitol/sorbitol/lactose/glucose are common stabilizers and freeze-drying aids, making the claim more likely to be implicated |
| Use of redispersion in manufacturing |
If the competitor uses a “reconstitution in manufacturing” step that amounts to redispersion before solidification, it can map onto the process limitation |
| Stability advantage language |
Comparative statements can be used to distinguish prior art and argue nonobviousness, but they also provide litigation hooks for testing |
How to read the dependency in Claim 2
Claim 2 locks comonomer ratio = 75/25. That is narrower than Claim 1’s broader about 100/0 to 50/50 window. A product falling within Claim 1 but outside 75/25 would still be assessed under Claim 1, not Claim 2.
Claim structure and enforcement posture
The patent uses:
- method-of-use/process (Claim 1),
- process-defined product (Claim 3),
- parameter narrowing (Claim 2).
This structure often leads to enforcement targeting either:
- the manufacturer’s process documentation, or
- comparative stability test results paired with formulation characterization to prove the presence of each limitation.
Key Takeaways
- US Patent 5,631,020 claims a specific sustained-release injectable microcapsule method built on PLGA (defined comonomer ratio and molecular weight), spherical particle size 2–200 μm, a defined excipient set, and a required redispersion then solidification sequence.
- The claims are payload-restricted to (Pyr) Glu-His-Trp-ser-Tyr-D-Leu-Leu-Arg-Pro-NH-C2 H5, which is the strongest narrowing feature for freedom-to-operate.
- Claim 3 is product-by-method, so the process steps in Claim 1 remain central in infringement analysis.
- The “greater stability vs no redispersion” comparative limitation is a litigation focal point and typically drives both prosecution differentiation and infringement testing strategy.
FAQs
1) Does Claim 5,631,020 cover any PLGA microcapsule formulation?
No. Claim 1 requires specific PLGA parameters, specific particle size, an explicit excipient set, a redispersion then solidification sequence, and the exact water-soluble peptide identified in the claim.
2) Can a competitor avoid coverage by changing PLGA molecular weight?
Yes, if the PLGA molecular weight falls outside about 5,000 to 200,000, the formulation will not meet Claim 1’s matrix specification.
3) Is the excipient choice flexible under the claims?
No. Claim 1 restricts the excipient used in the redispersion step to mannitol, sorbitol, lactose, or glucose.
4) What role does the “greater stability” language play?
It is an outcome limitation: the reconstituted microcapsule must show greater stability than a counterpart where no redispersion step is performed.
5) How does Claim 3 expand coverage beyond Claim 1?
It does not broaden materially. Claim 3 covers the microcapsule produced by the method of Claim 1, so Claim 1’s full set of limitations remains the practical boundary.
References
[1] U.S. Patent 5,631,020, “Method for producing a prolonged release microcapsule for injection,” claims 1-3.
